InhibRx

28 articles about InhibRx

• bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies

  1/7/2019

  The small size of sdAbs may enable the generation of more complex CAR T cell products such as those designed to combine additional functions into a single CAR molecule or recognize multiple tumor antigens simultaneously.

• Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)

  12/6/2018

  -Interim data expected in 1H 2019-

• Inhibrx Wins CARB-X Award of Up to $6M To Accelerate Development of its Novel Antibody, INBRX-111, to Treat Pseudomonas Infections

  10/31/2017

  InhibRx announced today a significant collaboration with CARB-X.

• OncoSec Medical Announces First Technology Access Program Agreement With Inhibrx

  3/14/2017

• Inhibrx Adopts DNASTAR Lasergene Software

  3/29/2016

• Inhibrx And The Alpha-1 Project Collaborate To Develop A Recombinant Alpha-1 Antitrypsin With Improved Properties

  9/17/2015

• Five Prime and Inhibrx Ink $452.5 Million Cancer Deal Focusing on GITR Antibodies

  7/17/2015

• Oxford Finance Closes $20 Million Debt Facility With Inhibrx

  4/10/2015